AcquisitionOther
Merck acquired Terns Pharmaceuticals, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Merck -> Terns Pharmaceuticals, Inc. · $6.7 billion
To expand hematology pipeline with TERN-701, a novel BCR::ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia.
Open source record (SEC) ↗